Shares of genome-medicine company Sangamo Therapeutics (SGMO - Get Report) surged Tuesday after the company nd Pfizer (PFE - Get Report) announced "encouraging" results from a phase 1-2 study of a gene therapy for the treatment of a severe type of hemophilia.

The company announced in a press release that its SB-525 developed with Pfizer was "generally well tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts. 

"These interim results suggest that SB-525 may be well-tolerated and may prove to have the predictability and sustained treatment effect that can bring clinical benefit in patients with hemophilia A," Sangamo Chief Medical Officer Edward Conner said in a statement.

We'll be hosting a conference call and webcast today at 8:00 a.m. ET to discuss our clinical program and other corporate updates. Here is more information: $SGMO

— Sangamo Therapeutics (@SangamoTx) April 2, 2019

Separately, Sangamo announced that early data for another gene-editing therapy called ST-400, developed in partnership with pharmaceutical company Sanofi, were also progressing well. It also provided an update on its AAV manufacturing capacity and capabilities.

Shares of Sangamo jumped 38.1% to $13.16 in trading Tuesday.

How Much Money Will I Need to Retire?

Want to learn about retirement planning from some of the nation's top experts? Join TheStreet's Robert "Mr. Retirement" Powell live in New York on April 6 for our Retirement Strategies Symposium. For a limited time, tickets are available for $99 for this full-day event. Check out the agenda, learn about the speakers and sign up here.